The ArrestAD Team

The program brings together an international consortium with academic and clinical research teams of high levels coming from different European universities: Université Paris-Est Créteil (France), Universidad Autónoma de Barcelona (Spain), Universidad de Salamanca (Spain), Radboud University Medical Centre Nijmegen (Netherlands), the University of Liverpool (England) and include in addition the institute of Memory and Alzheimer Disease from the Assistance Publique-Hôpitaux de Paris (France), the NENCKI Institute of Experimental Biology of Warsaw (Poland), and a French industrial partner Paris-based, the SME ScreenCell.

Principal investigator of each partner:

Professor of Biochemistry and Glycosciences at UPEC. Head of the research unit “Growth, Repairing and Regeneration of Tissues” – CRRET (UPEC). Her group works to advance in the comprehension of the mechanisms implicating natural sulfated glycosaminoglycans (GAGs), particularly heparan sulfates and their biosynthetic enzymes, in regenerating or degenerating tissues. The team studies the positive or negative functional consequences that GAGs structural changes can provoke in pathological conditions or during aging.

Professor of Neurology at the Neurological Institute of the University Salpêtrière Hospital in Paris, University Pierre & Marie Curie (UPMC). He is Director of the Institute for Memory and Alzheimer Disease” (IM2A), of the Expert Memory Center Paris-Sud and of the Research INSERM Unit on “Cognition and Neuroimaging in Brain Diseases” at the ICM (Institut du Cerveau et de la Moelle Epinière) at the Salpêtrière Hospital. IM2A is a clinical research center, dedicated to early diagnosis, to pathophysiological research and treatment of Alzheimer’s disease, related diseases, and dementia.

Full Professor and a Head of Laboratory of Advanced Preclinical Research of Higher Standard at the Center for Neurobiology of the Nencki Institute in Warsaw. The laboratory own research program concentrates on molecular mechanisms of Alzheimer’s disease (AD) with a special emphasis on the role of aberrant cell cycle regulation and calcium signaling impairment. These processes are being studied at the genomic, proteomic, and cellular levels. The laboratory also investigate systemic changes in AD, mainly in blood lymphocytes. These studies aim at identification of early disease markers and design of new therapeutic strategies in AD. Moreover, as lack of human neuronal models has so far limited preclinical drug testing, they develop and evaluate novel models employing human induced Pluripotent Stem Cells (iPSC).

  • Prof. Georges Uzan : ScreenCell (SCell), Sarcelles (France)

Chief Scientific Officer (CSO) of ScreenCell company. SCell has developed a size based large cells purification technology, which is innovative, non-invasive, reliable, easy to use and affordable. This is a point of care technology, which does not require any additional equipment. The system is able to preserve the viability, proliferation and invasion potential of isolated cells (Dessiter et al, 2011). By providing an easy access to fixed or live circulating large cells, the ScreenCell devices allow the access to a full range of technologies enabling phenotypical, genotypical, and functional characterization of these cells.

Associated Professor of Psychiatry at UAB, Head of the Medical Psychology Unit. Her research (Quality Research Group, SGR1354 2014), is focused in Behavioral Neuroscience and Biological Psychiatry in the Department of Psychiatry & Forensic Medicine and the Institute of Neuroscience.

Associate professor at the Department of Biochemistry, head of the section Matrix Biochemistry. The Matrix Biochemistry group is at the cutting edge of developments in matrix molecules and their role in pathology. Focus is on glycosaminoglycans including heparan sulfate, and over the years a number of new technologies to analyse these molecules have been developed. One of the tools developed are phage display derived antibodies to heparan sulfate, for which the group has been internationally acknowledged.

Staff scientist and faculty member of the Cancer Research Cancer and the University of Salamanca (USAL), PI and director of the Bioinformatics and Functional Genomics Research Group at the Cancer Research Center (CiC-IBMCC). His  research group work is dedicated to develop and apply bioinformatics to the study of omic data derived from biomedical studies (with a main focus on complex diseases), and to promote translation of basic research advances to clinical applications at the level of diagnostics, prognostics or treatment. The FICUS Foundation supports special units for bioinformatics, genomics and proteomics, providing investigators the access to the latest analysis technologies for omics data.

Professor of Biological Chemistry at University of Liverpool. David Fernig’s Group belong to The Institute of Integrative Biology at the University of Liverpool. His research group is focus on the Molecular Basis of Therapeutic Targetting theme, and is dedicated to understanding the molecular basis of disease associated with abnormal interactions between proteins and complex sugars (termed glycans) and translating fundamental knowledge to the bedside.